GT Biopharma, Inc. to Discuss Innovative Therapies for AML and MDS
Exciting News in the Field of Immuno-Oncology
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD, from the University of Minnesota Medical School and GT Biopharma’s Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also be participating in 1×1 meetings during the event.
Looking Towards the Future of Cancer Treatment
This announcement marks a significant step forward in the development of cutting-edge therapies for patients suffering from AML and MDS. The TriKE® platform, with its focus on harnessing the power of natural killer cells to target cancer cells, holds great promise for improving outcomes and quality of life for individuals facing these challenging diagnoses.
Dr. Miller’s participation in the panel discussion highlights the collaborative efforts of researchers, clinicians, and industry professionals to advance the field of immuno-oncology. By sharing insights and expertise, these experts are paving the way for new treatment options that may revolutionize the standard of care for patients with hematologic malignancies.
As the healthcare community continues to explore the potential of immunotherapy and targeted therapies, events like the ROTH Healthcare Opportunities Conference provide a valuable forum for knowledge exchange and networking. GT Biopharma’s presence at this event signifies their commitment to driving innovation and addressing unmet medical needs in the field of oncology.
How This Will Impact Me
As a patient diagnosed with AML or MDS, the discussions and developments presented at the 3rd Annual ROTH Healthcare Opportunities Conference could have a direct impact on your treatment options and overall prognosis. By staying informed about the latest advancements in immuno-oncology, you may have access to potentially life-saving therapies that could improve your outcomes and quality of life.
How This Will Impact the World
The work being done by GT Biopharma and other industry leaders in the field of immuno-oncology has the potential to revolutionize cancer treatment on a global scale. By developing novel therapies that target specific cancer cells while sparing healthy tissue, researchers are moving closer to personalized medicine approaches that could benefit patients worldwide.
Conclusion
The participation of Dr. Jeffrey Miller and GT Biopharma in the upcoming panel discussion on innovative therapies for AML and MDS represents a significant milestone in the field of immuno-oncology. By collaborating and sharing insights, researchers and industry professionals are paving the way for new treatment options that have the potential to transform cancer care. As we look towards the future, the promise of personalized medicine and targeted therapies offers hope for improved outcomes and quality of life for patients facing hematologic malignancies.
